The spray – which was approved by the FDA in March – has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ICER.
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
According to Janssen the drug will cost £10,790 per Quality ... patient's age and other factors. Spravato is approved as an adjunctive therapy administered by a nasalspray and is based on ...
Some results have been hidden because they may be inaccessible to you